The tech giants’ Q2 earnings might be behind us, but there is still plenty of intrigue left among those yet to report the second quarter’s financials to keep avid Street watchers satisfied.  One such company sure to draw attention this week will be ACADIA Pharmaceuticals (ACAD), due to announce the quarter’s display on Wednesday (Aug 4, AMC). While investors be keen to gauge the company’s financial health, ears will be pricking up to hear what’s new regrading Nuplazid, Acadia’s potential treatment for patients with dementia-related psychosis (DRP).
https://www.tipranks.com/news/article/acadia-the-streets-gaze-turns-to-fda-meetings-outcome-on-drp-treatment?utm_source=advfn.com&utm_medium=referral
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Nov 2021 to Dec 2021 Click Here for more Acadia Pharmaceuticals Charts.
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Dec 2020 to Dec 2021 Click Here for more Acadia Pharmaceuticals Charts.